ITPP pre-order

This is a pre-order product. New batch will be finished by the mid of August, 2024. Orders containing ITPP will be shipped after the specified date. We’re sorry for long wait and false promises about restock in the beginning of summer but the war in our country makes its own adjustments.
Myo-inositol trispyrophosphate (ITPP) was developed as an allosteric effector of hemoglobin to locally increase partial oxygen pressure. ITPP binds to band 3 proteins on red blood cells and leads to a shift of the erythrocyte intracellular pH toward acidic values. This triggers a decrease in the affinity of oxygen to hemoglobin, which results in an increased release of oxygen upon tissue demand. Subsequent to this rapidly induced and long-term physicochemical effect, ITPP normalizes the tumor vasculature on downregulation of proangiogenic factors such as HIF-1a and VEGF. In addition, ITPP selectively activates the tumor suppressor PTEN in endothelial cells, thereby inhibiting signaling downstream of PI3K and subsequently normalizing the tumor vasculature.